

COUNSELLORS AT LAW 28 STATE STREET BOSTON, MASSACHUSETTS 02109-1784

TELEPHONE (617) 227-7400 FAX (617) 742-4214 lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997) THOMAS V. SMURZYNSKI RALPH A: LOREN GIULIO A. DeCONTI, JR. ANN LAMPORT HAMMITTE ELIZABETH A, HANLEY AMY BAKER MANDRAGOURAS ANTHONY A. LAURENTANO KEVIN J. CANNING JANE E. REMILLARD DeANN FORAN SMITH PETER C. LAURO DEBRA J. MILASINCIC, Ph.D. DAVID J. RIKKERS DAVID R. BURNS JOHN S. CURRAN SEAN D. DETWEILER MEGAN E. WILLIAMS, Ph.D.

LISA M. DIROCCO HATHAWAY P. RUSSELL . MARIA LACCOTRIPE ZACHARAKIS, Ph.D. MERIDETH C. ARNOLD DANIELLE L. HERRITT **ELIMOON LEE \*\*** 

SENIOR COUNSEL JAMES E. COCKFIELD

OF COUNSEL JEREMIAH LYNCH WILLIAM A. SCOFIELD, JR. SIBLEY P. REPPERT JEANNE M. DIGIORGIO CYNTHIA L. KANIK, Ph.D.

PATENT AGENTS THEODORE R WEST CYNTHIA M. SOROOS PETER W. DINI, Ph.D. JONATHAN M. SPARKS, Ph.D.

TECHNICAL SPECIALISTS CATHERINE M. RISHOR JACOB G. WEINTRAUB CRISTIN E. HOWLEY, Ph.D. JILL ANN MELLO PLO DEBORAH L. NAGLE, Ph.D. ANNE JACQUELINE NOWAK, Ph.D. ANDRINA WILLIAMS ZINK

July 8, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Re:

U.S. Patent Application No.: 10/010942

TECH CENTER 1600/2900 For: HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID

PEPTIDE

Inventors: Basi, Guriq et al. Filed: December 6, 2001 Our Ref. No.: ELN-002

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

Supplemental Information Disclosure Statement; 1.

2. PTO Form 1449:

3. Copies of references cited in PTO Form 1449 (7);

A copy of the International Search Report; and 4.

5. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any other necessary fees due in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this

purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22813-1450 on: Rebra J. Milasino ., Registration No. 46,931

Respectfully submitted

Debra. Milasincic, Esq. Registration No. 46,931 Attorney for Applicants



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Basi, Guriq et al.

Serial No.: 10/010942

Filed: December 6, 2001

For: HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE

Attorney Docket No.: ELN-002

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Group Art Unit: 1645

Examiner: Not Yet Assigned

RECEIVED
TECH CENTER 1600/2900

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

July 8, 2003

Date of Signature and of Mail Deposit

By: Debra J. Milasincic, Esq.

Reg. No. 46,931

Attorney for Applicants

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney have become aware of the following publications and information, cited in an International Search Report mailed April 17, 2003 during the prosecution of PCT/US01/46587 which corresponds to the above referenced application. In accordance with 37 CFR §1.97, Applicants hereby submit these publications for the Examiner's consideration. These publications are cited on the enclosed PTO Form 1449, and a copy of the Report and each publication cited thereon are enclosed as well.

Serial Number: 10/010942 Page -2- Group Art Unit: 1645

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(e)(1), the undersigned hereby certifies that each item contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application *for the first time* not more than three months prior to the filing of this statement.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account

No. 12-0080.

Respectfully submitted LAHIVE & COCKEIN

Debra J. Milasincic, Esq. Registration No. 46,931 Attorney for Applicants

28 State Street Boston, MA 02109 (617) 227-7400

Date: July 8, 2003

AEM/DJM/CEH/krj

**Enclosures** 

REV 7-80		PUBLICATIONS CITE	RTMENT OF E ND TRADEMARK OFFICE	ELN-002		serial no. 10/010942	et 1 of 1	द्ध	
	(	Use several sheets if	necessar	y)	Basi, Guriq et al.		GROUP 1645		
					December 6,	2001	1645	्रे,	003
			U.S. F	PATENT DOCI	JMENTS			000	2
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO	
	<u> </u>						<u> </u>		
			FOREIG	N PATENT DO	CUMENTS				
		DOCUMENT NUMBER	DATE		Country	CLASS	SUBCLASS	TRANS	LATIO
<del>-</del>	/B1	JP 7-165799	06/95	Japan				YES Abstract	
<del>                                     </del>	B2	WO 00/23082 A1	04/00	WO	<del>.</del>			Only	_
<b>—</b>	∙B3	WO 00/72880 A2,A3	05/00	wo			<u> </u>		_
<u> </u>	В4	WO 02/088306 A2	11/02	WO			•		<del> -</del>
`	B5	WO 02/088307 A2	11/02	WO					
		OTHERS (inc	ludina A	sther Title De	to Dominant Da		<u> </u>		
	B6	Bard, F. et al. "Per	ipherally	administered	te, Pertinent Pa antibodies agai	iges, <i>⊑τc.)</i> nst amvloid β-i	pentide ente	r the cer	ntral
,		nervous system ar 6(8):916-919 (Aug	nd reduce	e pathology in	a mouse mode	l of Alzheimer	disease," Na	ature Me	dici
	B7	Kettleborough, C.A	eborough, C.A. et al. "Humanization of a mouse monoclonal antibody by CDR-grafting: the rtance of framework residues on loop conformation," Protein Engineering 4(7):773-783						the
				· <u>-</u>					-
<u> </u>	$\vdash$	<del>                                     </del>		<del>-</del>					
						<u> </u>			
	ll								
	$\vdash$								
				<u> </u>		<u></u>			

Examiner		Date Considered
*EXAMINER:	Initial if reference considered, whether or n if not in conformance and not considered.	ot citation is in conformance with MPEP 609; Draw line through citation Include copy of this form with next communication to applicant.